Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2022-12-09 00:00:00+00:00 | ABBV | Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates | This week, a U.S. district court dismissed thousands of lawsuits involving the heartburn drug Zantac, pushing up stocks of GSK GSK, Sanofi SNY and Pfizer PFE. Pfizer/BioNTech received FDA’s emergency approval for Omicron BA.4/BA.5-adapted COVID vaccine for kinds under five years of age. Pfizer and AbbVie ABBV announced... |
2022-12-09 00:00:00+00:00 | ABBV | Have $1,000? 2 Top Dividend Stocks to Buy Right Now | Even in the current inflationary environment, where stocks across a wide variety of sectors are trading down, companies with a favorable history of growing investor returns in a range of markets are still ripe for the taking.
If you're looking to add more dividend stocks to your portfolio this month, it's important to ... |
2022-12-09 00:00:00+00:00 | ABBV | Notable Friday Option Activity: ABBV, FCX, ITGR | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 24,265 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 44.3% of ABBV's average daily trading volume over ... |
2022-12-08 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains But Lags Market: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $165.99, marking a +0.36% move from the previous day. This change lagged the S&P 500's 0.75% gain on the day. At the same time, the Dow added 0.55%, and the tech-heavy Nasdaq lost 0.01%.
Heading into today, shares of the drugmaker had gained 12.04% over the past mo... |
2022-12-08 00:00:00+00:00 | ABBV | 2 Forever Stocks You Can Buy and Forget About | If you're investing for the very long term (i.e., forever), then the good news is you don't need to worry about what's happening with the economy. Over the years, the economy has recovered from wars, recessions, and everything else in between. While many businesses have failed during that time, companies with solid fun... |
2022-12-08 00:00:00+00:00 | ABBV | 3 Hot Stocks That Could Live Up to Their Lofty Valuations | Green Thumb Industries (OTC: GTBIF), SunPower (NASDAQ: SPWR) and Genmab (NASDAQ: GMAB) are all up this month, and are trading for at least 35 times earnings. Instead of being overpriced, though, there are solid reasons investors see potential in these hot stocks.
All three have debt-to-equity ratios below 0.90 and doub... |
2022-12-06 00:00:00+00:00 | ABBV | Unsubstantiated price hikes drove U.S. drug spending up $805 mln in 2021-report | By Bhanvi Satija
Dec 6 (Reuters) - Price increases spread among seven of the 10 drugs in 2021 behind an $805 million increase in U.S. spending from the prior year were not supported by clinical evidence, an influential U.S. pricing research firm said on Tuesday.
The Institute for Clinical and Economic Review (ICER) sai... |
2022-12-06 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +10.7%, compared to the Zacks S&P 500 composite's +6.2% change. During th... |
2022-12-06 00:00:00+00:00 | ABBV | AbbVie Signs License Agreement With HotSpot For Use Of IRF5 In Autoimmune Diseases | (RTTNews) - AbbVie Inc. (ABBV) announced Tuesday an exclusive worldwide collaboration and option to license agreement for HotSpot Therapeutics Inc.'s discovery-stage IRF5 transcription program for the treatment of autoimmune diseases.
The IRF5 acts as a key regulator of certain types of immune responses and its dysregu... |
2022-12-06 00:00:00+00:00 | ABBV | Is AbbVie Stock a Buy Now? | Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. But it's not as if the company didn't see this coming and didn't prepare for it.
As a result, the pharmaceutical stock is up more than 36% so far this year ... |
2022-12-06 00:00:00+00:00 | ABBV | Is Johnson & Johnson Stock A Better Pick Over Its Peer? | We believe Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Eli Lilly stock (NYSE: LLY), given its better prospects. Although Eli Lilly is trading at a comparatively higher valuation of 11.8x trailing revenues than 4.8x for J&J, this gap in the valuation to some extent is justified given Eli Lilly’s... |
2022-12-05 00:00:00+00:00 | ABBV | New Investor? Buy These 2 Growth Stocks | If you are a new investor who has heard about the market's turbulence this year, you might be hesitating to invest at all. Most growth stocks got a beating this year. But a tumultuous market is a high-opportunity place to buy excellent stocks at a discounted price and hold them for the long haul.
It would be wise for n... |
2022-12-05 00:00:00+00:00 | ABBV | Is AbbVie Stock a Smart Contrarian Pick for 2023? | Imagine that someone asks you to invest in a business. This business has been highly successful in the past. However, its top-selling product accounts for nearly 38% of total revenue. And sales for that product are about to tank due to competition.
Do you invest in the business? I suspect most people would take a pass ... |
2022-12-04 00:00:00+00:00 | ABBV | Here's How to Prepare Your Portfolio for 2023 | One of the biggest questions investors may have right now is: Will the bear market end in 2023? Unfortunately, no one can answer that question. The good news is that history offers us some clues about how long bear markets usually last -- and the average is about one year. So we know these troubled times generally are ... |
2022-12-03 00:00:00+00:00 | ABBV | 3 Stocks to Buy Hand Over Fist in December | High conviction. That's what you want to have with the stocks you buy. Such stocks are ones that you can be enthusiastic about -- and buy heavily.
We asked three Motley Fool contributors to identify stocks for which they have high convictions about buying right now. Here's why they think that AbbVie (NYSE: ABBV), Exeli... |
2022-12-02 00:00:00+00:00 | ABBV | Stocks To Invest In Right Now? 3 Biotech Stocks To Watch | If you didn’t know, biotech stocks have been on the rise in recent years, as investors seek out companies that are developing groundbreaking new treatments for a wide range of diseases. Biotech firms are often at the forefront of medical research, and their products have the potential to transform the lives of patients... |
2022-12-02 00:00:00+00:00 | ABBV | ABBV Crosses Above Average Analyst Target | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $161.27, changing hands for $161.63/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... |
2022-12-02 00:00:00+00:00 | ABBV | FOCUS-Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot | By Michael Erman
Dec 2 (Reuters) - U.S. drugmaker Merck & Co MRK.N hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling drug from competition expected as soon as 2028.
For years Merck has relied on Keytruda to fue... |
2022-12-01 00:00:00+00:00 | ABBV | Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report? | It has been about a month since the last earnings report for Pfizer (PFE). Shares have added about 6.5% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Pfizer due for a pullback? Before we dive into how investors and analysts have r... |
2022-12-01 00:00:00+00:00 | ABBV | AbbVie To Present At Piper Sandler 34th Annual Healthcare Conference; Webcast At 9:30 AM ET | (RTTNews) - AbbVie (ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference.
The event is scheduled to begin at 9:30 AM ET on December 1, 2022.
To access the live webcast, log on to http://investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the author and do ... |
2022-12-01 00:00:00+00:00 | ABBV | AbbVie Announces Provincial Reimbursement For RINVOQ For Rheumatoid Treatment | (RTTNews) - AbbVie Inc. (ABBV) Thursday announced provincial reimbursement for RINVOQ for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan.
In addition, RINVOQ is now listed as a Limited Use product on the formulary of the Non-Insured Health Benef... |
2022-11-30 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy in Case the Santa Rally Doesn’t Come | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The Santa Claus rally is a noted phenomenon whereby the stock market tends to rally during the week leading up to Christmas. Many theories about the reason for the phenomenon have been posited including optimism from the holiday spirit, increased shopping, ... |
2022-11-30 00:00:00+00:00 | ABBV | XLV, ABBV, CVS, ELV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $522.3 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 3... |
2022-11-30 00:00:00+00:00 | ABBV | 3 Top Dividend Kings to Buy for the Long Haul | This year has been particularly difficult for the stock market, making investors more hesitant to invest their hard-earned money. Dividend stocks, on the other hand, are popular among investors because these investments are typically stable and secure. Such investments are also a simple way to earn consistent income ev... |
2022-11-30 00:00:00+00:00 | ABBV | Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now? | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the iShares Core High Dividend ETF (HDV) is a smart beta exchange traded fund launched on 03/29/2011.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitalizatio... |
2022-11-29 00:00:00+00:00 | ABBV | FOCUS-Rare success for Alzheimer's research unlocks hope for future therapies | By Julie Steenhuysen
CHICAGO, Nov 29 (Reuters) - The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical exe... |
2022-11-29 00:00:00+00:00 | ABBV | AbbVie To Present At Evercore ISI Virtual HealthCONx Conference; Webcast At 10:55 AM ET | (RTTNews) - AbbVie (ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference.
The event is scheduled to begin at 10:55 AM ET on November 29, 2022.
To access the live webcast, log on to http://investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the author... |
2022-11-29 00:00:00+00:00 | ABBV | 3 Reasons Pfizer Stock Will Crush the Broader Market in 2023 | Pfizer (NYSE: PFE) is a 173-year-old company with a huge portfolio of products. But the company truly became a household name rather recently -- in the early days of the pandemic. That's because Pfizer is the leader in the coronavirus vaccine and treatment market. And those products are set to generate more than $56 bi... |
2022-11-28 00:00:00+00:00 | ABBV | Here's What's Driving AbbVie's (ABBV) Outperformance This Year | AbbVie ABBV stock has risen 17.9% this year so far compared with an increase of 8.5% for the industry.
Image Source: Zacks Investment Research
AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed Abb... |
2022-11-28 00:00:00+00:00 | ABBV | AbbVie’s (NYSE:ABBV) Loss Could be CVS’s (NYSE:CVS) Gain | AbbVie’s (NYSE:ABBV) popular drug Humira is losing ground in the international markets due to competition from biosimilars. While ABBV’s Humira faces challenges, a Wall Street Journal report highlighted that pharmacy-benefit managers (PBMs) like CVS Health’s (NYSE:CVS) Caremark and UnitedHealth’s (NYSE:UNH) Optum Rx wo... |
2022-11-27 00:00:00+00:00 | ABBV | 8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income | There is no one-size-fits-all strategy that has the potential to make investors wealthy over time, but there are few approaches that have a better track record of success than investing in dividend stocks.
Companies that pay dividends are often successful, profitable businesses -- year in, year out -- which have genera... |
2022-11-26 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Hold Forever | Some dividend stocks have staying power. You can count on them to pay dividends quarter after quarter as well as deliver solid growth over the long term.
We asked three Motley Fool contributors to identify dividend stocks that you can hold forever. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE:... |
2022-11-25 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +3.8%, compared to the Zacks S&P 500 composite's +6.2% change. Dur... |
2022-11-25 00:00:00+00:00 | ABBV | Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication | This week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone marrow diseases. The European Commission approved AbbVie’s ABBV immunology medicine, Skyrizi for its third indication, Crohn’s disease, in Europe. GSK GSK has begun the process to withdraw its approved multiple myeloma d... |
2022-11-24 00:00:00+00:00 | ABBV | Is Now the Time for Income Investors to Buy This Big Pharma Stock? | Though the COVID-19 pandemic still isn't definitively over, the work of large pharmaceutical companies to bring vaccines and treatments to market has restored confidence throughout most of the world. For the first time since early 2020, life has resumed more of a normal routine in recent months.
Much of that debt of gr... |
2022-11-24 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease | AbbVie ABBV announced that the European Commission has granted approval to its drug Skyrizi (risankizumab) to treat moderate-to-severe Crohn’s disease (“CD”).
Crohn’s disease is the third approved indication for Skyrizi in Europe. The drug is the first specific IL-23 inhibitor approved for CD in the European Union. The... |
2022-11-24 00:00:00+00:00 | ABBV | This Pharmaceutical Company Is A Better Pick Over Johnson & Johnson Stock | We think AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Both companies are comparable in terms of valuation, with AbbVie trading at 4.7x trailing revenues, and J&J trading at 4.6x. A similar valuation for both companie... |
2022-11-23 00:00:00+00:00 | ABBV | Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today. | An easy way to boost your income is through dividend stocks. Since they pay a percentage of your investment back to you every quarter, you're collecting cash on a regular basis, and you don't have to sell your investment, either. If you invest in dividend growth stocks, you can even see your income rise over the years ... |
2022-11-23 00:00:00+00:00 | ABBV | ABBV January 2023 Options Begin Trading | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the January 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2023 contracts and identified one put and one call contract of particular interest.
The put c... |
2022-11-23 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie PepsiCo, The Walt Disney, Caterpillar and PBF Energy | For Immediate Release
Chicago, IL – November 23, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, PepsiCo... |
2022-11-23 00:00:00+00:00 | ABBV | 2 Safe Dividend Stocks to Buy Hand Over Fist | The stock market has been fairly volatile over the past three years, which isn't surprising given the worldwide crises we have experienced. Further, the economy continues to face challenges, such as high inflation and the possibility of a coming recession. It might be tempting to give up on investing in stocks in this ... |
2022-11-23 00:00:00+00:00 | ABBV | Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar? | Launched on 03/29/2011, the iShares Core High Dividend ETF (HDV) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Blackrock. It has amassed assets over $12.64 billion, making it one of the larger ETFs attemp... |
2022-11-23 00:00:00+00:00 | ABBV | AbbVie Boosts Its Dividend: Is the Dividend King a Buy? | The global economic and geopolitical environment is far from certain right now, with elevated inflation throughout the world and the ongoing conflict between Russia and Ukraine. And if there's anything that the market craves, it is certainty. This goes some way to explaining why the S&P 500 index is down about 18% so f... |
2022-11-23 00:00:00+00:00 | ABBV | AbbVie: SKYRIZI (risankizumab) Gets EU Approval To Treat Moderate To Severe Active Crohn's Disease | (RTTNews) - AbbVie (ABBV) announced Wednesday that the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe active Crohn's disease.
It is the first specific interleukin-23 or IL-23 inhibitor in the European Union for the treatment of adults with moderately to severely active Crohn... |
2022-11-22 00:00:00+00:00 | ABBV | FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars | By Natalie Grover and Steven Scheer
Nov 22 (Reuters) - Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of ... |
2022-11-22 00:00:00+00:00 | ABBV | The Health Care Select Sector SPDR Fund Experiences Big Inflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $323.1 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 3... |
2022-11-22 00:00:00+00:00 | ABBV | Top Stock Reports for AbbVie, PepsiCo & Walt Disney | Tuesday, November 22, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS). These research reports have been hand-picked from the ... |
2022-11-22 00:00:00+00:00 | ABBV | Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | By Brendan Pierson
Nov 22 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N have finalized the terms of settlements worth more than $6.6 billion to resolve thousands of lawsuits by U.S. state and local governments over the marketing of opioid painkillers, the companies and lawyers for the gov... |
2022-11-22 00:00:00+00:00 | ABBV | 2 Reasons to Buy AbbVie Stock and 1 Reason to Sell | As the developer of some of the world's highest-grossing medicines, AbbVie (NYSE: ABBV) stands as a pharmaceutical titan, and its stock could be a good fit for many different types of investors' portfolios. Between its huge pipeline and its history of profitable operations, everyone from passive income investors to tho... |
2022-11-22 00:00:00+00:00 | ABBV | AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag | AbbVie ABBV and partner Genmab GMAB announced that the FDA has accepted and granted priority review to its biologics license application (BLA) seeking approval for epcoritamab for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBCL is a common form of non-... |
2022-11-22 00:00:00+00:00 | ABBV | Want Passive Income in 2023? Buy These Dividend Kings | Today's market is tough. And your portfolio may be suffering. But if you invest in dividend stocks, the picture may begin to look brighter. These companies pay you annually -- just for owning their shares. So, in good times and in bad, you can rely on this passive income to lift the value of your holdings.
Where do you... |
2022-11-21 00:00:00+00:00 | ABBV | 3 Top Dividend Stocks to Buy Now With Yields of 3.4% or More | Are you looking for reliable dividend-paying stocks that offer juicy yields and the ability to raise their payouts much further by the time you're ready to retire? If so, these three stocks from the healthcare and finance sectors have you covered.
Right now all three of these top dividend stocks offer yields above the ... |
2022-11-20 00:00:00+00:00 | ABBV | If You Invested $5,000 In InMode Stock In 2020, Here's How Much Money You'd Have Today | InMode (NASDAQ: INMD) is a growth stock unlike any other, and it's also one of my biggest holdings. This medical aesthetics company hails from Israel, and it makes technologies that enable minimally invasive beauty treatments, ranging from skin tightening to body contouring. That means it stands to steal market share f... |
2022-11-19 00:00:00+00:00 | ABBV | 2 Breakout Growth Stocks to Buy for the Long Haul | Definitive Healthcare (NASDAQ: DH) and Elevance Health (NYSE: ELV) may not be household names, but these two healthcare stocks in the Russell 1000 Index are prime examples of breakout growth stocks that investors should be considering.
Other than their strong prospects, the two stocks aren't much alike. Definitive, fou... |
2022-11-18 00:00:00+00:00 | ABBV | CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron | Shares of clinical-stage, oncology-focused biopharmaceutical company CytomX Therapeutics, Inc. CTMX skyrocketed 32.2% after the company announced a collaboration and licensing agreement with biotech giant, Regeneron Pharmaceuticals, Inc. REGN.
Both companies have collaborated to create conditionally-activated investiga... |
2022-11-17 00:00:00+00:00 | ABBV | Key Factors Driving Amgen's (AMGN) Outperformance This Year | Amgen AMGN stock has risen 38.2% this year so far against a decline of 23.4% for the industry.
Image Source: Zacks Investment Research
Here we discuss the factors for the stock's outperformance. Amgen’s key drugs like Prolia, Repatha and Otezla are aiding sales, driven by volume growth. These drugs are gaining consist... |
2022-11-16 00:00:00+00:00 | ABBV | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | The First Trust Morningstar Dividend Leaders ETF (FDL) was launched on 03/09/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.28 billion, making it o... |
2022-11-15 00:00:00+00:00 | ABBV | 3 Pharmaceutical Stocks For Your November 2022 Watchlist | Pharmaceutical stocks are an important part of any well-rounded investment portfolio. They offer the potential for both high returns and low risk, making them ideal for investors of all types. Pharmaceutical stocks are a good investment for many reasons.
For one, the global population is aging, and as people age, they ... |
2022-11-14 00:00:00+00:00 | ABBV | Noteworthy Monday Option Activity: BA, CHRD, ABBV | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Boeing Co. (Symbol: BA), where a total of 55,921 contracts have traded so far, representing approximately 5.6 million underlying shares. That amounts to about 54.9% of BA's average daily trading volume over the ... |
2022-11-14 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +5.1%, compared to the Zacks S&P 500 composite's +11.4% change. During th... |
2022-11-13 00:00:00+00:00 | ABBV | Is A Fall Imminent For Merck Stock After A 12% Rise In A Month? | Merck stock (NYSE: MRK) is up 12% in a month, outperforming the broader S&P500 index, up 5%. The rise in MRK stock can be attributed to the upbeat Q3 earnings it reported in late October. Its top and bottom line were well above our estimates, driven by market share gains for some of its drugs.
Merck’s revenue of $15.0 ... |
2022-11-13 00:00:00+00:00 | ABBV | The 7 Best Stocks for Retirement | With corporate pensions largely becoming an anachronistic relic, it’s never been more important for investors to plan for their golden years. However, with the combination of broader market volatility and the Federal Reserve’s interest rate hikes (and all that this action encompasses), the backdrop practically bolsters... |
2022-11-13 00:00:00+00:00 | ABBV | 2 Top Stocks to Buy in November and Hold Forever | Earnings reports can be an investor's best friend. They don't just tell us about recent revenue and profit. They also offer us clues about a company's future. These reports don't have to be 100% positive. But if certain important points are bright, we might be looking at a buying opportunity.
That's the case for both A... |
2022-11-11 00:00:00+00:00 | ABBV | XLV, UNH, ABBV, ELV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $599.8 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 3... |
2022-11-10 00:00:00+00:00 | ABBV | See Which Of The Latest 13F Filers Holds AbbVie | At Holdings Channel, we have reviewed the latest batch of the 28 most recent 13F filings for the 09/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... |
2022-11-09 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2022-11-09 00:00:00+00:00 | ABBV | This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy. | AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. They're outperforming the S&P 500 index. But the stock has lost a bit of ground since AbbVie's third-quarter earnings report in late October.
The pharmaceutical company noted a slowdown in one of its key businesses -- aesthetics... |
2022-11-09 00:00:00+00:00 | ABBV | If You Like Dividends, You Should Love These 3 Stocks | The growth stock boom of 2021 left some investors wondering if dividend stocks were still prudent holdings to drive long-term returns. Then 2022 came along and answered that concern quite clearly.
Dividend stocks are lynchpins in a diversified portfolio because of their many advantages, including:
Most dividend stocks ... |
2022-11-08 00:00:00+00:00 | ABBV | Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks | Dividend stocks are rarely the lightning-growth companies that many investors seem to gravitate toward, but these types of investments certainly have an allure of their own. Whether providing additional capital that you can put back into your portfolio again and again, or increasing your total returns with time, the be... |
2022-11-08 00:00:00+00:00 | ABBV | These 3 Dividend ETFs Are a Retiree's Best Friend | Dividend exchange-traded funds (ETFs) give income-focused investors an attractive alternative to bonds or stocks, particularly during periods when the latter two are struggling.
Most dividend ETFs invest in a variety of dividend-paying stocks, and many of the most popular ETFs track blue-chip companies with solid divid... |
2022-11-08 00:00:00+00:00 | ABBV | The 7 Best Pharma Stocks to Buy Now | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stoc... |
2022-11-07 00:00:00+00:00 | ABBV | AbbVie : Phase 2 Trial Of AGN-151607 In POAF In Cardiac Surgery Patients Fails To Meet Main Goal | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. The primary endpoint of evaluating the occurrence of ... |
2022-11-05 00:00:00+00:00 | ABBV | 3 Reasons to Buy AbbVie Stock Right Now | Despite the market downturn, pharma giant AbbVie (NYSE: ABBV) has performed well this year. The company's shares are up 8% in the past 10 months, easily beating the broader market. But can AbbVie maintain this pace? One of the bears' favorite arguments is that the healthcare company will lose U.S. patent exclusivity fo... |
2022-11-04 00:00:00+00:00 | ABBV | 3 Dividend Kings Crushing the S&P 500 in 2022 | Income investors love to target Dividend Aristocrats, companies that have increased their dividend payouts for a minimum of 25 consecutive years.
However, a step above is the elite Dividend Kings group, companies with at least 50 consecutive years of increased dividend payouts.
Clearly, companies in the Dividend King c... |
2022-11-04 00:00:00+00:00 | ABBV | Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 28 cents per share in third-quarter 2022, beating the Zacks Consensus Estimate of 27 cents. The company reported adjusted earnings of 33 cents per share in the year-ago quarter.
Total revenues of $109 million missed the Zacks Consensus Estimate of $112 m... |
2022-11-04 00:00:00+00:00 | ABBV | Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View | Amgen AMGN reported third-quarter 2022 earnings of $4.70 per share, which beat the Zacks Consensus Estimate of $4.43 as well as our estimate of $4.37 per share. Earnings rose 15% year over year. Lower operating expenses and share count boosted earnings in the quarter.
Total revenues of $6.65 billion also beat the Zacks... |
2022-11-04 00:00:00+00:00 | ABBV | 2 Dividend Growth Stocks to Buy and Hold for Years | Did you know that a stock which increases its dividend by 7% will double its payout in a decade? That's the power of investing in dividend growth stocks. Over time, their yields will rise and investors can earn much more on their initial investment. That can make a low-yielding stock look deceptively low.
Two stocks th... |
2022-11-04 00:00:00+00:00 | ABBV | Better Buy: AbbVie vs. Walgreens Boots Alliance | Whether you're looking for passive income or for growth, both AbbVie (NYSE: ABBV) and Walgreens Boots Alliance (NASDAQ: WBA) might be of interest. The pair pay decent dividends, operate with business models that are proven to be sustainable over time, and aren't in deep danger of running afoul of longstanding economic ... |
2022-11-04 00:00:00+00:00 | ABBV | 3 Top Healthcare Stocks to Buy for November | The end of the year is right around the corner. But this time of year actually is a beginning for certain healthcare stocks. That's because important share-performance catalysts and/or revenue opportunities lie just ahead. And that's why these players make great buys in November.
CRISPR Therapeutics (NASDAQ: CRSP) is s... |
2022-11-02 00:00:00+00:00 | ABBV | 3 Year-End Investing Strategies You Should Consider Right Now | In a perfect world, the calendar wouldn't matter when it comes to investing. Companies would always be fairly valued based on their future prospects, and major price swings would be rare events driven by substantial changes to those prospects. In the real world, however, the calendar matters. Investors make decisions o... |
2022-11-02 00:00:00+00:00 | ABBV | Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever | Whether you're looking to make some extra dough from dividend income or build defensive investments into your portfolio, Dividend Kings are stocks you should know about these days. What they all have in common is this: they've raised their dividends for at least 50 (yup, 50) consecutive years.
The capacity to build suc... |
2022-11-02 00:00:00+00:00 | ABBV | 5 Stocks to Watch on Recent Dividend Hikes Amid High Volatility | Major U.S indexes like the S&P 500, the Dow and the Nasdaq continued to gyrate in the month of October after a disappointing this year till September. Though the stock market recovered in October, the overall sentiment of investors remains cautious ahead of the Federal Reserve’s meeting this week.
The Fed is expected ... |
2022-11-01 00:00:00+00:00 | ABBV | CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims - sources | By Brendan Pierson
Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... |
2022-11-01 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +5.8% over the past month versus the Zacks S&P 500 composite's +8.1% change. The Zacks ... |
2022-11-01 00:00:00+00:00 | ABBV | These 2 Passive Income Stars Just Declared Dividend Raises | Investors are now in the midst of the final earnings season of 2022. Companies often cap their reporting year with a dividend raise, and the raising has been relatively brisk lately. Businesses of every size and in every sector are adding to their payouts.
Two giants in their respective industries, AbbVie (NYSE: ABBV) ... |
2022-11-01 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy Hand Over Fist in November | There's just something comforting about a stock that pays you to own it. That's especially the case amid the current overall stock market volatility.
I'm talking, of course, about dividend stocks. Well over 4,000 stocks traded on U.S. exchanges offer dividends. But some are better than others. Here are three dividend s... |
2022-10-28 00:00:00+00:00 | ABBV | Daily Dividend Report: AAPL,BKR,ABBV,ROK,WBA | Apple's board of directors has declared a cash dividend of $0.23 per share of the Company's common stock. The dividend is payable on November 10, 2022 to shareholders of record as of the close of business on November 7, 2022.
Baker Hughes announced today that the Baker Hughes Board of Directors declared an increased qu... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q3 2022 Earnings Call Transcript | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q3 2022 Earnings Call
Oct 28, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie's third quarter 2022earnings conference call [Operator ins... |
2022-10-28 00:00:00+00:00 | ABBV | Friday's ETF with Unusual Volume: DEF | The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. Shares of DEF were up about 2% on the day.
Components of that ETF with the highest volume on Friday were Gilead Sciences, trading up about 11.3... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View | AbbVie Inc. ABBV reported earnings of $3.66 per share for the third quarter of 2022, beating both the Zacks Consensus Estimate and our estimate of $3.56 and $3.57, respectively. The reported earnings also exceeded the guidance of $3.55-$3.59. Earnings rose 29.3% year over year.
ABBV’s revenues of $14.81 billion missed ... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relapsed/refractory Diffuse Large B-cell | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q3 Earnings Beat Estimates | AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. This compares to earnings of $3.33 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 2.81%. A quarter ago, it was e... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie Q3 22 Earnings Conference Call At 9:00 AM ET | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... |
2022-10-28 00:00:00+00:00 | ABBV | AbbVie Q3 Profit Increases, beats estimates | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates.
The company's earnings came in at $3.949 billion, or $2.21 per share. This compares with $3.179 billion, or $1.78 per share, in last year's third quarter.
Excluding items, AbbVie reported adjus... |
2022-10-28 00:00:00+00:00 | ABBV | Health Care Sector Update for 10/28/2022: DVA, ABBV, SNY, XLV, IBB | Health care stocks were flat to lower premarket Friday. The Health Care SPDR (XLV) was flat and the iShares Biotechnology Index (IBB) was recently inactive.
DaVita (DVA) was down more than 18% after it reported Q3 adjusted earnings of $1.45 per diluted share, down from $2.36 a year earlier. Analysts polled by Yahoo! Fi... |
2022-10-27 00:00:00+00:00 | ABBV | Pfizer Earnings Preview: Growth & Diversification is Key | Pfizer’s PFE Q3 earnings report on November 1 will give insight into the company’s ability to sustain growth from its Covid-19 vaccines. Vaccinations gave PFE a boost during the pandemic with the stock up nicely over the last few years.
Post-pandemic, revenue from Covid-19 vaccines may eventually start to fade and inve... |
2022-10-27 00:00:00+00:00 | ABBV | AbbVie Q3 Preview: Can Shares Continue Their Run? | The Zacks Medical sector has performed slightly better than the S&P 500 YTD, down 18.7% vs. the general market’s roughly 20% decline.
A titan in the realm, AbbVie ABBV, is on deck to unveil Q3 earnings on October 28th, before the market open.
AbbVie enjoys leadership positions in key therapeutic areas, including immuno... |
2022-10-27 00:00:00+00:00 | ABBV | Pre-Market Earnings Report for October 28, 2022 : XOM, CVX, ABBV, NEE, SNY, CL, AON, CHTR, IMO, GWW, LYB, CHD | The following companies are expected to report earnings prior to market open on 10/28/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2022. The oil company's consensus earnings per share forecast from the 9 ... |
2022-10-27 00:00:00+00:00 | ABBV | XLV, ABBV, ELV, MDT: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $203.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 2... |
2022-10-26 00:00:00+00:00 | ABBV | 2 Monster Stocks to Buy Without Any Hesitation | Hesitation. That's a key word in the investment community right now. Many investors are hesitating before buying stocks. This bear market isn't over. And investors worry even the strongest stocks may fall further. That's as problems such as higher inflation weigh on companies and their customers.
It's important to reme... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.